Patient characteristic | Value |
---|---|
Male:female | 31:22 |
Tumour subtype | |
Adenocarcinoma | 21 (40%) |
Squamous cell carcinoma | 24 (45%) |
Not specified | 8 (15%) |
T status | |
T1 | 6 (11%) |
T2 | 14 (27%) |
T3 | 15 (28%) |
T4 | 17 (32%) |
Tx | 1 (2%) |
N status | |
N0 | 11 (21%) |
N1 | 4 (8%) |
N2 | 33 (62%) |
N3 | 5 (9%) |
Tumour stage | |
IB | 3 (6%) |
IIB | 5 (9%) |
IIIA | 24 (45%) |
IIIB | 21 (40%) |
Median interval between 18F-FDG PET and start of treatment (days) | 45 (range 0–174) |
Median radiotherapy dose (Gy) | 64 (range 55–64) |
Median chemotherapy cycles | 4 (range 1–6) |